Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
Abstract
No abstract available.
Author
Citations
Altmetric:
Date
2022-03-01
Type
Article
Subject
multiple myeloma, renal impairment, selinexor, bortezomib, dexamethasone
Collections
Citation
Delimpasi, S., Mateos, M. V., Auner, H. W., Gavriatopoulou, M., Dimopoulos, M. A., Quach, H., Pylypenko, H., Hájek, R., Leleu, X., Dolai, T. K., Sinha, D. K., Venner, C. P., Benjamin, R., Garg, M. K., Doronin, V., Levy, Y., Moreau, P., Chai, Y., Arazy, M., Shah, J., … Grosicki, S. (2022). Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. American journal of hematology, 97(3), E83–E86. https://doi.org/10.1002/ajh.26434